← News

Boltz raises $110 million to sell AI drug design by the token

Boltz, which builds AI models that predict and design molecules for drug discovery, raised a $110 million Series A led by Bessemer Venture Partners. It says six of the world's 20 largest pharma companies are paying customers.

Most AI drug-discovery companies hoard their models and do one-off pharma deals. Boltz is betting molecules can be sold like API calls. The 50x usage jump is its own number, but Pfizer and GSK paying is a real signal.

On Wednesday, Nov. 18, Boltz announced a $110 million Series A led by Bessemer Venture Partners. A Series A is an early round from venture firms, once a company has a product people are already using. Bessemer's Andrew Hedin and Byron Deeter are joining. The investors already on the cap table came back in: Andreessen Horowitz, Amplify Partners, Zetta Venture Partners, and Obvious Ventures. New checks include Greycroft, F-Prime Capital, Hummingbird, and Benchling. The announcement does not print a valuation, the price the round implies for the whole company. The size and that investor list are Boltz's.

The customer line is the company's too. Boltz says it has partnerships with six of the world's 20 largest pharma companies, including Pfizer, GSK, Takeda, and BMS. BMS is Bristol Myers Squibb. Bessemer spells that last name out and lists the same four.

Use of the paid product jumped, by Boltz's count. Molecular token usage among paying customers has grown 50-fold since June. Fifty-fold means fifty times the June pace. A token, here, is a unit of model work the company charges for, the way a text model charges for a chunk of writing. The jump followed the June release of Boltz's first proprietary models, BoltzMol-1 and BoltzProt-1. Proprietary means these ones are Boltz's to sell, not the free models it had already published. Andreessen Horowitz describes the same climb as roughly 50-fold over the last four months. The multiple is the company's, however the window is worded.

The product people open is Boltz Lab, which launched in January and puts the models on a web page a scientist can use. The Boltz API, a hook other software can call, runs inside tools a lab already has, including agent tools such as Claude Code and Codex. An agent tool, here, is software that can take a series of steps, not only answer one question. Bessemer and Andreessen Horowitz both describe that setup. The business model is usage-based. Boltz charges for the model work, and the scientists keep ownership of what they create. That ownership line is Andreessen Horowitz's account of the model.

The founders came out of a university lab. Gabriele Corso is chief executive. Jeremy Wohlwend and Saro Passaro are the other co-founders. Bessemer says the three were core developers of the open-source models from Professor Regina Barzilay's lab at MIT. Open-source, here, means the models were published so other people could run them. Bessemer says those models have been downloaded more than 5 million times. Boltz says the company grew from a small group of MIT researchers to about 40 people in just over a year.

Where the money goes, in the company's words: more compute and more data, enough capacity to meet what partners are already asking for, and a larger team. Compute is the rented machine time the models need. The goal Boltz states is a scientist going from a therapeutic hypothesis, an idea for a medicine, to a molecule ready for people, without leaving the computer. That last step is the company's ambition, not a result it says it has delivered.

The picture is the three co-founders standing in a bright office, in black shirts with a small white mark, plants and pendant lights behind them. All three faces are in the frame, and the group sits right of center. The announcement does not say which person is which. It is the photograph on Bessemer's Nov. 18 post. The credit is Bessemer Venture Partners.

In plain terms, an MIT group that already gave away widely used protein models raised $110 million to charge for the next ones, by the token, instead of locking them inside one drug pipeline. The 50-fold usage jump is Boltz's number. Pfizer, GSK, Takeda, and Bristol Myers Squibb on the customer list is a real name-check, and it is still the company's.

RELATED

ONLINE…

Comments

guidelines

Loading…

Loading…

Sources